NasdaqGM:AUPHBiotechs
Aurinia Pharmaceuticals (AUPH) Launches PRESERVE Study, Is A 5% Undervalued View Enough?
Aurinia Pharmaceuticals (AUPH) is drawing fresh attention after announcing PRESERVE, a Phase 4 multicenter study testing its oral lupus nephritis drug LUPKYNIS alongside three established immune therapies.
See our latest analysis for Aurinia Pharmaceuticals.
The PRESERVE announcement comes after a strong period for Aurinia Pharmaceuticals, with a 1 year total shareholder return of 113.70% and a more moderate 5.67% year to date share price return. This suggests momentum that investors are now...